Product Description
CD31 Antibody [C31.12] | 33-573 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Human full length recombinant protein was used as the immunogen for this CD31 antibody.
Research Area: Cancer, Immunology, Signal Transduction
Tested Application: WB, Flow, IF
Application: Flow Cytometry: 0.5-1ug/10^6 cells
IF: 1-2 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD31 antibody to be titered up or down for optimal performance.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: C31.12
Isotype: IgG1
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Platelet endothelial cell adhesion molecule, PECAM-1, EndoCAM, GPIIA', PECA1, CD31, PECAM1
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: CD31 (PECAM-1) is a transmembrane glycoprotein member of the immunoglobulin supergene family of adhesion molecules. CD31 is expressed by stem cells of the hematopoietic system and is primarily used to identify and concentrate these cells for experimental studies as well as for bone marrow transplantation. Anti-CD31 has shown to be highly specific and sensitive for vascular endothelial cells. Staining of nonvascular tumors (excluding hematopoietic neoplasms) is rare. CD31 mAb reacts with normal, benign, and malignant endothelial cells which make up blood vessel lining. The level of CD31 expression can help to determine the degree of tumor angiogenesis, and a high level of CD31 expression may imply a rapidly growing tumor and potentially a predictor of tumor recurrence.